https://scholars.lib.ntu.edu.tw/handle/123456789/628932
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | ZHONG-ZHE LIN | en_US |
dc.contributor.author | Hu, Mickey C-T | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | YAO-MING WU | en_US |
dc.contributor.author | YEN-SHEN LU | en_US |
dc.contributor.author | Ho, Ja-An Annie | en_US |
dc.contributor.author | Shiou-Hwei Yeh | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.date.accessioned | 2023-03-06T00:32:07Z | - |
dc.date.available | 2023-03-06T00:32:07Z | - |
dc.date.issued | 2023-03-01 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/628932 | - |
dc.description.abstract | The telomerase-specific oncolytic adenovirus Telomelysin and the histone deacetylase inhibitor AR42 have demonstrated anticancer effects in preclinical models of human hepatocellular carcinoma (HCC). However, the clinical development of Telomelysin may be hindered by human antiviral immunity and tumor resistance. Combining oncolytic and epigenetic therapies is a viable approach for treating various cancers. This study investigated the potential synergism of Telomelysin and AR42 and the relevant underlying mechanisms. Telomelysin and AR42 exhibited synergistic antiproliferative effects in human HCC models in vitro and in vivo. Apoptosis induced by Telomelysin was significantly enhanced by AR42 in both PLC5 and Hep3B HCC cells. AR42 treatment unexpectedly attenuated the expression of the coxsackievirus and adenovirus receptor and the mRNA levels of human telomerase reverse transcriptase, which may be positively associated with the cytotoxicity of Telomelysin. Meanwhile, the cellular antiviral interferon response was not altered by AR42 treatment. Further, we found that Telomelysin enhanced Akt phosphorylation in HCC cells. AR42 reduced Telomelysin-induced phospho-Akt activation and enhanced Telomelysin-induced apoptosis. The correlation of Akt phosphorylation with drug-induced apoptosis was validated in HCC cells with upregulated or downregulated Akt signaling. Combination therapy with Telomelysin and AR42 demonstrated synergistic anti-HCC efficacy. Clinical trials investigating this new combination regimen are warranted. | en_US |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER IRELAND LTD | en_US |
dc.relation.ispartof | Cancer letters | en_US |
dc.subject | Akt; HDAC inhibitor; Hepatocellular carcinoma; Oncolytic adenovirus; Telomelysin | en_US |
dc.title | Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.canlet.2023.216063 | - |
dc.identifier.pmid | 36669725 | - |
dc.identifier.scopus | 2-s2.0-85147352134 | - |
dc.identifier.isi | WOS:000926848000001 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85147352134 | - |
dc.relation.journalvolume | 556 | en_US |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Medical Service-NTUCC | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Center for Quality Management and Infection Control-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.dept | Surgery-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Clinical Trial Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Microbiology | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0002-1720-7863 | - |
crisitem.author.orcid | 0000-0001-7461-1291 | - |
crisitem.author.orcid | 0000-0003-4509-180X | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。